Moderna, Inc. (MRNA) Stock Grade

About Moderna, Inc.'s fundamentals

Moderna is a biotechnology company with an $11.5 billion market capitalization that reported a significant net loss in its latest annual statement, resulting in a negative net margin of -145.2%. The company experienced substantial revenue contraction, declining 39.2% year-over-year, indicating a marked reduction in sales. The company does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not applicable given the loss position. These metrics reflect the company's current unprofitable operations and the challenge of declining revenues.